Medindia

X

Hologic Announces Upcoming Put Option and Notice of Redemption of 2.00% Convertible Exchange Senior Notes Due 2037

Thursday, November 10, 2016 Senior Health News J E 4
Advertisement

MARLBOROUGH, Mass., Nov. 9, 2016 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX) announced today that holders of the 2.00% Convertible Exchange Senior Notes due 2037 (CUSIP No. 436440 AB7) issued November 23, 2010 have the right to surrender their notes for repurchase by the Company.  This right is pursuant to the put option under the base indenture governing the notes dated December 10, 2007, as supplemented by the second supplemental indenture dated November 23, 2010 (collectively, the indenture).

The put option entitles each holder of the notes to require the Company to repurchase in cash all or part (in principal amounts equal to $1,000 or multiples thereof) of the notes on December 15, 2016 (the put option repurchase date) at a price equal to 100% of the original principal amount of the notes, plus accrued and unpaid interest, if any, upon the terms and subject to the conditions set forth in the indenture and the notes. Unless the Company defaults on the payment, interest on notes surrendered for repurchase will cease to accrue on and after December 15, 2016. As of November 9, 2016, there was $8,436,000 aggregate principal amount of the Notes outstanding.

The opportunity to exercise the put option commences on November 16, 2016 at 9 a.m. Eastern Time (ET), and expires at 5 p.m. ET on December 14, 2016 (the expiration date), which is the business day immediately preceding the put option repurchase date. Holders may withdraw any notes previously surrendered for repurchase at any time prior to 5 p.m. ET on the expiration date. To exercise the put option, or withdraw notes previously surrendered, a holder must follow the procedures set forth in the put right notice that is being delivered to all registered holders of the notes.

None of the Company, its board of directors or employees has made, or is making, any representation or recommendation to any holder of the notes as to whether to exercise the put option.

Notice of Redemption

In addition, the Company announced today that it has issued a notice of redemption to the holders of the notes to redeem any notes outstanding on December 19, 2016 (the redemption date) pursuant to its option under Section 11.01 of the supplemental indenture and Article 11 of the base indenture. As a result, notes that are not surrendered to the Company for repurchase as described above, or that are not surrendered for conversion prior to 5 p.m. ET on December 16, 2016, will be redeemed by the Company on the redemption date at a price equal to 100% of the accreted principal amount of the notes plus accrued and unpaid interest up to, but not including, the redemption date.  This redemption will be upon the terms and subject to the conditions set forth in the indenture and the notes. Unless the Company defaults on the payment of the redemption price, interest on such notes will cease to accrue on and after the redemption date, and the only remaining right of the holders of the notes will be to receive payment of the redemption price.

Conversion Right and Net Share Settlement Election

Pursuant to the terms of the indenture, holders of the notes have a right to convert them at any time prior to 5 p.m. ET on December 16, 2016, which is the business day immediately preceding the redemption date, subject to the terms, conditions and adjustments set forth in the indenture and the notes. The current conversion rate for the notes is 43.4216 shares of the Company's common stock per $1,000 principal amount outstanding, which is equivalent to a conversion price of approximately $23.03 per share.

The Company also announced today that it has irrevocably elected to settle any conversion of the notes entirely in cash pursuant to Section 12.02(a)(ii) of the supplemental indenture.  This irrevocable election applies only to the 2037 notes, and does not apply to any other convertible notes of the Company.

Additional Information

At the Company's request, Wilmington Trust Company, the trustee, paying agent and conversion agent for the notes, is delivering a put right notice and notice of redemption to all registered holders of the notes. In addition, the Company will file these notices with a tender offer statement on Schedule TO with the Securities and Exchange Commission today. Copies of these notices and additional information relating to the procedure for the surrender, conversion and/or redemption of the notes may be obtained from Wilmington Trust Company as provided below.

For the notice of redemption

Wilmington Trust CompanyRodney Square North1100 North Market Street - 5th FloorWilmington, DE 19890Attention: Corporate Capital Markets - Workflow Mgmt

For the put right notice

Wilmington Trust CompanyRodney Square North1100 North Market StreetWilmington, DE 19890Attention: Workflow Mgmt - 5th FloorTelephone: (302) 646-6470Facsimile: (302) 636-4139

About Hologic

Hologic, Inc. is a developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products. The Company's core business units focus on diagnostics, breast health, GYN surgical, and skeletal health. With a unified suite of technologies and a robust research and development program, Hologic is dedicated to The Science of Sure. For more information on Hologic, visit www.hologic.com.

Hologic and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

Contact

Michael WattsVice President, Investor Relations andCorporate Communications (858) 410-8588

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/hologic-announces-upcoming-put-option-and-notice-of-redemption-of-200-convertible-exchange-senior-notes-due-2037-300359496.html

SOURCE Hologic, Inc.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
SciClone Reports Third Quarter 2016 Financial Resu...
S
Hanson Research Releases New Phase One™ Disintegra...